IMV Inc.
IMV Inc.
Your view on IMVIF
Overview
What the company does, where it operates, and who runs it.
About IMV Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andrew Hall
- Headquarters
- 130 Eileen Stubbs Avenue, Dartmouth, NS, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andrew Hall
- Headquarters
- 130 Eileen Stubbs Avenue, Dartmouth, NS, CA
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers.
The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer.
It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for IMV Inc., and the rating behind it. IMVIF last traded at $0.0000; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for IMV Inc.. Starting points for IMV Inc.: EPS -$4.43, beta 0.34 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for IMV Inc.. IMV Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for IMV Inc.. Trailing twelve-month EPS for IMV Inc. stands at -$4.43. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for IMV Inc.. IMV Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
IMV Inc. valued side by side against its closest peers. IMV Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold IMV Inc., and how their positions are changing. At a $117 market value, institutional positions materially move IMV Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by IMV Inc. executives and directors. Shares of IMV Inc. have traded between $0.0000 and $0.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming IMV Inc.. IMV Inc. is a $117 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming IMV Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for IMV Inc.. Coverage tracks IMV Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.